Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma

Cancer molecular heterogeneity might explain the variable response of EGFR mutant lung adenocarcinomas to tyrosine kinase inhibitors (TKIs). We assessed the mutational status of 22 cancer genes by next-generation sequencing (NGS) in poor, intermediate or good responders to first-line gefitinib. Clin...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncotarget
Asıl Yazarlar: Bria, Emilio, Pilotto, Sara, Amato, Eliana, Fassan, Matteo, Novello, Silvia, Peretti, Umberto, Vavalà, Tiziana, Kinspergher, Stefania, Righi, Luisella, Santo, Antonio, Brunelli, Matteo, Corbo, Vincenzo, Giglioli, Eliana, Sperduti, Isabella, Milella, Michele, Chilosi, Marco, Scarpa, Aldo, Tortora, Giampaolo
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Impact Journals LLC 2015
Konular:
Clinical Research Paper
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4494974/
https://ncbi.nlm.nih.gov/pubmed/25904052
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller